All News

GSK, Spero Therapeutics, resubmitted an NDA for tebipenem HBr, an oral carbapenem antibiotic, for treating complicated UTIs, supported by phase 3 trial data.

ASCO’s new guideline outlines evidence-based strategies for diagnosing and treating leukemia and lymphoma during pregnancy.

A multidisciplinary initiative increased prenatal iron deficiency screening 6-fold and intravenous iron treatment 20-fold.

The FDA has granted 510(k) clearance to the FemVue Controlled device, enabling in-office ultrasound assessment of fallopian tube status.

In a recent study, states enforcing abortion bans without health exceptions saw significant increases in obstetric-related EMTALA violations.

A network meta-analysis found that adding magnetic bead auricular point therapy, electroacupuncture, or steroids to epidural analgesia reduces the risk of maternal fever during labor.

A study found that objective blood loss assessment detects postpartum hemorrhage more frequently than subjective visual estimation.

Standardized second-trimester ultrasound screening for vasa previa showed high sensitivity, specificity, and perinatal survival across large cohorts.

A study found women aged 65 years and older had significantly greater odds of late-stage cervical cancer.

A meta-analysis found transabdominal cerclage was linked to lower perinatal mortality and preterm birth than transvaginal cerclage.

The FDA approved flibanserin for HSDD in women younger than 65 years, expanding access to the first nonhormonal therapy for low sexual desire.

A study found heavy menstrual bleeding and meat-restricted diets are associated with increased rates of iron deficiency among adolescents.

A study found that the monoclonal antibody HMI-115 significantly reduced dysmenorrhea and pelvic pain in women with endometriosis.

A study shows acute heavy menstrual bleeding frequently requires transfusion and carries significant treatment costs.

Edward Hook, MD, discusses the FDA approval of oral zoliflodacin and its role in expanding treatment options for uncomplicated gonorrhea amid rising resistance.

The FDA has approved Nuzolvence as a new single-dose oral option for uncomplicated urogenital gonorrhea in adults and children 12 years and older who weigh at least 77 pounds

Review some of the top stories from the Contemporary OB/GYN website over the past week and catch up on anything you may have missed.

George L. Maxwell, MD, outlines the SUNFLOWER phase 3 trial assessing Mirena vs oral progestin for treating nonatypical endometrial hyperplasia.

Phase 3 results show oral zoliflodacin was non-inferior to ceftriaxone and azithromycin for uncomplicated urogenital gonorrhea.

This approval of gepotidacin is the first in a new antibiotic class for the treatment of gonorrhoea approved in over 3 decades.

A study found first-trimester anatomy screening enables earlier identification of congenital anomalies, indicating a need for updated guidance.

A phase 2 trial found the maternal GBS-AlpN vaccine to be immunogenic and have an acceptable safety profile in pregnant women and their infants.

DARE to PLAY sildenafil cream is now available for prescribing in select states as a non-hormonal topical option to improve genital blood flow and arousal.

Large US cohort finds women with uterine fibroids had more than 80% higher 10-year cardiovascular disease risk than women without fibroids.

A study found continuing metformin through the first trimester was linked to greater clinical pregnancy rates in women with PCOS.

A study found thyroid hormone imbalance across multiple pregnancy trimesters was associated with increased autism spectrum disorder risk in children.

Melanie Barrett, MD, highlights brexanolone’s ability to quickly and durably reduce depressive and anxiety symptoms in postpartum women.

New research shows that obesity-related increases in estrone after menopause may drive inflammation and tumor growth.